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Abstract 
Circulating tumor cell (CTC) and cell-free (cf) DNA-based genomic alterations are 
increasingly being used for clinical decision-making in oncology. However, the 
concordance and discordance between paired CTC and cfDNA genomic profiles 
remain largely unknown.  We performed comparative genomic hybridization (CGH) on 
CTCs and cfDNA, and low-pass whole genome sequencing (lpWGS) on cfDNA to 
characterize genomic alterations (CNA) and tumor content in two independent 
prospective studies of 93 men with mCRPC treated with enzalutamide/abiraterone, or 
radium-223. Comprehensive analysis of 69 patient CTCs and 72 cfDNA samples from 
93 men with mCRPC, including 64 paired samples, identified common concordant 
gains in FOXA1, AR, and MYC, and losses in BRCA1, PTEN, and RB1 between CTCs 
and cfDNA. Concordant PTEN loss and discordant BRCA2 gain were associated with 
significantly worse outcomes in Epic AR-V7 negative men with mCRPC treated with 
abiraterone/enzalutamide. We identified and externally validated CTC-specific 
genomic alternations that were discordant in paired cfDNA, even in samples with high 
tumor content. These CTC/cfDNA-discordant regions included key genomic regulators 
of lineage plasticity, osteomimicry, and cellular differentiation, including MYCN gain in 
CTCs (31%) that was rarely detected in cfDNA. CTC MYCN gain was associated with 
poor clinical outcomes in AR-V7 negative men and small cell transformation. In 
conclusion, we demonstrated concordance of multiple genomic alterations across 
CTC and cfDNA platforms; however, some genomic alterations displayed substantial 
discordance between CTC DNA and cfDNA despite the use of identical copy number 
analysis methods, suggesting tumor heterogeneity and divergent evolution associated 
with poor clinical outcomes.    
 







Circulating tumor cells (CTCs) are rare cancer cells that are shed in the peripheral 
bloodstream during metastatic dissemination and progression [1, 2]. Previous 
studies have suggested CTC enumeration could be useful for prognosis and clinical 
response assessments for patients with advanced cancer while providing valuable 
information for drug target identification, treatment monitoring, and exploring tumor 
heterogeneity [3-6]. Tumor-derived cell-free DNA (cfDNA) in serum or plasma likely 
originates from apoptotic, dead or dying tumor cells, and may constitute genetic 
information associated with tumor cell evolution and heterogeneity during treatment 
and metastatic progression [7, 8]. Despite the utility of CTC and cfDNA analyses, 
there are several major challenges inherent in the development of CTC or cfDNA 
biomarkers [9] for treatment selection in clinical studies, namely reproducibility, 
defining actionable targets, and consistency across platforms [10, 11].  While some 
studies have found concordance between selected cfDNA genomic alterations and 
paired tumor biopsies [12, 13], few studies have examined the consistency of whole-
genome alterations across paired CTC and cfDNA samples. 
 
Metastatic castration resistant prostate cancer (mCRPC) is a lethal and complex 
disease [6]. While most men initially respond to novel hormonal therapies, such as 
abiraterone acetate or enzalutamide, nearly all men with mCRPC relapse and 
develop resistant progression over 1-3 years [14].  In addition, cross-resistance 
between abiraterone and enzalutamide is common in >50% of patients who are 
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treated sequentially [15].  Thus, optimal delivery of these agents in the second-line 
setting could be facilitated by the development of predictive biomarkers of treatment 
response and resistance. For example, detection of AR-V7 in CTCs, an important 
splice variant in the androgen receptor, is associated with resistance to hormonal 
therapies abiraterone acetate and enzalutamide [16-19]. Yet, despite the importance 
of AR-V7 as a predictive biomarker, many men with AR-V7 negative disease have 
resistance to therapy or develop resistance over time that is currently unexplained by 
AR alterations [16, 17, 20].  Thus, novel approaches to detect de novo biomarkers 
are needed. CTC- and cfDNA-based methods are minimally invasive technologies 
that can provide longitudinal insight into tumor biology of individual patients and 
provide a source of biomarkers for mCRPC response and progression. 
 
Given the increasing number of systemic treatment options available for men with 
mCRPC, predictive biomarkers that report on the underlying tumor biology and 
potential drug sensitivity would be desirable to maximize benefit and minimize harm 
and cost [21, 22]. However, metastatic biopsies in men with mCRPC are challenging, 
invasive, may not result in enough metastatic tissue for analysis, and can be limited 
by tumor heterogeneity or plasticity [22]. Conversely, CTC DNA and cfDNA are a 
ready source of cancer cell DNA that can be noninvasively collected and profiled 
longitudinally for molecular analysis for association with outcomes and potential 
mechanisms of drug resistance [23, 24]. However, the concordance of genomic 
alterations between CTC DNA vs. cfDNA is not well established, and data 
reproducibility and concordance across similar cfDNA platforms has proven to be a 
major challenge [12, 25]. Further, CTCs and cfDNA may represent different sources 
of tumor tissue and, in theory, could provide unique readouts of cancer biology and 
tumor heterogeneity over time depending on the specific clinical context and 
biomarker.   
 
Recently, studies have characterized whole-genomic copy number alterations (CNA) 
in CTCs and cfDNA; however, no systematic assessments of paired CTC and cfDNA 
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exist, especially in men with mCRPC [8, 10, 12, 26-29]. To address this, we 
analyzed whole-genome CNA in paired CTCs and cfDNA from men with mCRPC. 
Here, we describe the frequency of chromosomal aberrations in men with mCRPC 
treated with abiraterone, enzalutamide, or radium-223 and focus on genomic regions 
with concordance and discordance in paired CTCs and cfDNA and their association 
with clinical outcomes. The frequency and reproducibility of CTC-discordant CNAs 
were confirmed in publicly- available clinical samples, where both DNA CNA and 
mRNA expression were available. Our findings suggest that CTCs may provide 
unique biologic insights into mCRPC heterogeneity and clinical outcomes that may 







Materials and Methods 
 
Patient selection 
We included two independent prospective cohorts of men with mCRPC, including 
men treated with radium-223 (NCT02204943) or abiraterone/enzalutamide 
(PROPHECY study [30], NCT02269982). All patients at study entry had mCRPC and 
progressive disease and were histologically confirmed to have prostate 
adenocarcinoma, evidence of metastases by clinical/radiographic, castrate levels of 
testosterone (<50 ng/dl), and evidence of cancer progression by computerized 
tomography/bone scan or prostate-specific antigen rises by The Prostate Cancer 
Clinical Trials Working Group (PCWG2) criteria [31]. PROPHECY patients were 
required to have two poor-risk features, including anemia, high LDH, high alkaline 
phosphatase, pain requiring opiates, PSA doubling time of <3 months, radiographic 
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progression, and prior abiraterone/enzalutamide therapy with planned cross-over to 
the other hormonal agent. For the radium-223 study, patients were excluded if they 
had visceral metastases, and men were eligible if they had more than two 
symptomatic bone metastases.  All patients provided informed consent under 
separate protocols approved by the Duke University Institutional Review Board (IRB, 
PROPHECY, and Radium-223) or the Weill Cornell Medical College IRB 
(PROPHECY). 
 
CTC DNA and cfDNA isolation 
CTCs were enumerated using the FDA-approved CellSearch platform in a Clinical 
Laboratory Improvement Amendments (CLIA)-approved laboratory [11].  Separately, 
for CTC isolation for copy number alteration (CNA) and aCGH, 7.5ml blood in EDTA 
tubes was diluted with blood lysis buffer (Gibco, A10492), centrifuged and washed 
with 0.5% BSA in PBS buffer, and incubated for 30 minutes at 4C° with Dyna Beads-
CD45 (Invitrogen, 11153D) to deplete leukocytes. The enriched cells were stained 
with an anti-EpCAM antibody (Serotek, AbD, CMA1870g) labeled with anti-Mouse 
IgG1 AlexaFluor-647 (Z25008, Invitrogen) and anti-Hu CD45 coupled to AlexaFluor-
488 (C1620, Leinco). Next, EpCAM+ and CD45- cells were sorted by flow cytometry 
[32]. Gating thresholds were set using unspiked and spiked EpCAM+ (T47D) cells 
into healthy volunteer blood. In parallel, peripheral blood mononuclear cells (PBMCs) 
were isolated from the blood collected in EDTA tubes for germline DNA analysis as 
controls for each CTC sample, diluted with PBS (1:1), and layered on 4ml of Ficoll-
Plaque (GE Healthcare, 17-1440). Ficoll-Plaque layers were washed and suspended 
in 100μl in Milli-Q-Water. For cfDNA isolation for CNA and aCGH, 2ml plasma was 
obtained from mCRPC patients and isolated using the QIAamp Circulating Nucleic 
Acid Kit (Cat No-55114, Qiagen) and quantified using Quant-iT™ PicoGreen™ 
dsDNA Assay Kit (Thermo Fisher Scientific, Cat no: P11496) by Tecan Infinite® 200 
PRO. CfDNA visualized on an Agilent 4200 TapeStation. Before hybridizing the 
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samples to the aCGH microarray, all DNAs were amplified by using the 
GenomePlex® Single Cell Whole Genome Amplification Kits (Sigma, WGA4) to the 
yield required for labeling (0.50μg/sample) according to Agilent’s aCGH manual. 
Amplified genomic DNA was visualized on 1.5% agarose gel to verify DNA ~200-
700bp (Figure S1). 
 
AR-V7 testing 
The Epic AR-V7 nuclear protein detection and JHU AR-V7 RNA based assays were 
used to detect AR-V7 in CTCs. A positive test for the Epic assay was defined as the 
presence of CTCs (CK+/-) expressing nuclear AR-V7 protein, as previously 
described [19, 33, 34]. The JHU AR-V7 assay is an RT-PCR based assay to detect 
AR-V7 mRNA expression [16, 30]. 
 
Array comparative genomic hybridization (CGH)   
Two-color probe-based aCGH was performed using Agilent Oligonucleotide Array-
based CGH for Genomic DNA Analysis (Sure Print G3 Human CGH array, 4x180K) 
[32]. Data were analyzed using the Agilent Cytogenomics Software, and all CNAs 
were manually analyzed [32]. CNAs were then cross-referenced with publicly-
available prostate cancer datasets using cBioportal [35]. The biological or clonality of 
CTCs genomic concordance (CNA present in CTCs were detected in cfDNA) and 
discordance (CNA present in CTCs, but not detected in paired cfDNA samples) were 
calculated by comparing CNA in CTCs and cfDNA. Next, to minimize the false 
positives result, stringent filtering criteria were applied by using a minimum 3+ 
contiguous probes distribution, and two independent calls were used to call a copy 
gain or loss event. Further, all genomic altered genes were assessed manually 
based on aCGH probe distribution within chromosomal aberrations region analyzed 
in the Agilent CytoGenomics software. In addition, genomic agreement and 
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disagreement between 64 CTCs and paired cfDNA CNAs (gain versus no gain, or 
loss versus no loss) from combined radium and PROPHECY studies were 
independently analyzed by Cohen’s Kappa method in Graph Pad prism software 
(Table S3). 
 
Low-pass whole genome sequencing, tumor content and copy number 
analysis in cfDNA 
Low-pass whole genome sequencing of 83 cfDNA from 73 mCRPC patients was 
generated using ThruPLEX DNA-seq kits according to the manufacturer's protocol 
with the Ion Torrent IonXpress barcode index and sequencing adapters. Libraries 
were quantified using an Agilent Bioanalyzer 2200 tape station with HS D1000 tape 
and sequenced with 16 samples per Proton PI chip on an Ion Proton sequencer.  
To determine the tumor content (TC) in cfDNA, we used a well-established method 
PRINCe (pan-cancer, rapid, inexpensive, whole-genome NGS of cfDNA approach) 
for tumor content determination and to identify focal CNAs in cfDNA from mCRPC 
patients’ samples via low coverage (~0.01x) through genome-wide CNAs analysis, 
where the least-squares based distance metric (LSS) was performed on whole-
genome copy number data, and guide the tumor content approximation with low 
tumor content samples (LSS < 0.1), where estimated tumor contents greater than 
8.75% by LSS analysis were considered as high tumor content as previously 
described by Daniel H. Hovelson et al., 2017 [36]. Focal CNAs were measured as 
CNAs 1.5–20 Mb long with the log2CNRatio cutoffs for genomic gain and loss 
analyzed in lpWGS were >= 0.50 and <= -0.50, respectively.  
 
Clinical Outcomes and Statistical Analysis 
Genomic CNA data from 40 baseline samples were grouped as copy gain, loss or 
neutral, and investigated for the presence of CNA and their associations with 
progression-free survival (PFS) with abiraterone/enzalutamide in the PROPHECY 
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study. Progression-free survival was defined as the date from registration to 
radiographic progression using PCWG2 criteria (26), clinical progression requiring a 
change in systemic therapy, or death, whichever came first.  Kaplan-Meier analysis 
was used to estimate the PFS distribution according to the presence of CTC DNA or 
cfDNA specific genomic alterations in men who were AR-V7 negative as defined by 
the Epic AR-V7 nuclear assay. The proportional hazards model was utilized to 
estimate the hazard ratios for PFS in men who were AR-V7 negative. Besides, 
Graph pad prism was used for plotting the graphs, and p-value calculation based on 



























Patients with mCRPC demonstrate heterogeneous cfDNA concentrations that 
correlate with CTC burden 
A total of 140 men with progressive mCRPC were consented and enrolled in two 
independent prospective studies prior to initiating a new systemic therapy. Patients 
were treated with enzalutamide or abiraterone acetate targeting androgen receptor 
signaling (n=120, PROPHECY clinical trial, NCT02269982) [19] or radium-223 
(n=20, radium-223 pharmacodynamic trial, NCT02204943) [37] targeting bone 
metastasis. As shown in Figure 1A and B (CONSORT diagrams), 93 of these men 
contributed either CTCs, cfDNA, or both in this analysis of the combined studies.  
Together, 32 patients contributed 64 time-matched/paired samples of both CTCs and 
cfDNA for the present concordance analysis.  In the PROPHECY study, men had a 
median age of 73 years (range 45-92), median PSA of 19ng/ml (0.08-4194); mean 
123, high alkaline phosphatase, prior abiraterone/enzalutamide therapy or 
radiographic progression, and 100% had bone metastases. In the radium-223 
prospective study, patients with mCRPC were enrolled with >2 symptomatic bone 
metastases. The median age was 72 years (range 54-86), median PSA was 50 
ng/ml (range 2-1896), and all patients had elevated serum alkaline phosphatase. A 
total of 95% of patients in the radium-223 study had prior enzalutamide, and 80% 
had prior abiraterone acetate/prednisone treatment. Tables S1-2 describe the 
baseline clinical characteristics of the radium-223 and PROPHECY cohorts of men 
with mCRPC, respectively. Figure 1 provides the CONSORT diagram for the 
patients included in the present analysis and describes the research plan in the 
combined cohort of 140 mCRPC men. A total of 52% (69/133) of mCRPC men at 
baseline had an unfavorable > 5 CTCs per 7.5mL blood by CellSearch criteria [6], 
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the median number of CTCs was 5 (Figure S2A), and 30 men had 0 CTCs detected 
by CellSearch criteria.   
 
Similar to CTC counts, we found a range of cfDNA concentrations (median 104 
ng/2ml, range 46-1,458 ng/2ml plasma) across all patients. In addition, unamplified 
cfDNA was visualized on Agilent TapeStation revealed two DNA bands between 
100-200bp and 500-700bp, where, no genomic DNA contamination was seen 
(Figure S3). We hypothesized that this variation in cfDNA concentration could be 
explained, at least in part, by the CTC count. We hypothesized that men with higher 
CTC burden would also have higher cfDNA concentrations [11]. To test this 
hypothesis, we examined the association of cfDNA concentrations with CTC 
enumeration by measuring cfDNA concentration among 90 mCRPC men. Consistent 
with our hypothesis, we found that the median cfDNA concentration was higher in 
the group of patients with >5 CellSearch CTCs (median 118 ng/2ml) in comparison 
to those men with <4 CTC (p-value = 0.003) (median 85 ng/2ml) (Figure S2B).  
 
Low-pass whole genome sequencing, an alternative approach for copy 
number and tumor content determination in mCRPC  
We next sought to evaluate tumor content CNAs in cfDNA. To do this, we first 
utilized a low-pass whole-genome sequencing method (lpWGS, coverage ~0.1x), 
which requires an input of cfDNA (1-5ng). We applied this technique to cfDNA 
isolated from 83 plasma samples from 73 men in the PROPHECY study (72 baseline 
and 11 progression) [19]. The tumor content was determined in cfDNA from whole-
genome sequencing data using the PRINCe method according to previously 
described methods [36]. After determining the tumor content in cfDNA, we compared 
the distribution of CellSearch CTCs in 68 baseline mCRPC men from PROPHECY 
study with low tumor content (lowTC) (n=40) and high tumor content (highTC) 
(n=28). We found that CellSearch CTC counts were significantly higher in highTC 
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cfDNA (p- value= 0.0001) in comparison to lowTC cfDNA samples (Figure S2C). 
While no significant differences in cfDNA concentration were noted in high vs. low 
TC samples (Figure S2D). Furthermore, to prove the hypothesis that men with 
higher CTC burden would also have higher tumor content, here, we examined the 
association of tumor content (lowTC vs. highTC) with CTC enumeration (0, 1-4 and 
>=5 CTC CellSearch) among 68 mCRPC men, and found that 71% (20/28) patients 
with highTC had >=5 CellSearch CTCs in comparison to those men with <4 CTC 
(Figure S2E). Finally, these data suggest that men with high CTCs tend to have a 
greater cfDNA tumor content. 
Using lpWGS, we detected the androgen receptor (AR) copy gain in 36% (30/83) of 
cfDNA samples. Of these, 70% (21/30) of patients with AR copy gain had highTC, 
while 30% (9/30) had lowTC in their paired cfDNA (File S1). Next, we compared 
cfDNA CNA reproducibility between aCGH and lpWGS by comparing whole genome 
and focal/gene-level copy number changes at the AR locus in 21 paired cfDNA 
samples from 15 mCRPC men (15 baseline and 6 progression) (Figure 1B). We 
identified high concordance (genomic alteration identified by both aCGH and lpWGS) 
of both AR copy gain detection (89%) and AR copy neutral status (92%) (Figure 
S4A-D). In highTC samples, AR gain detection was 67%, while in lowTC samples 
AR gain detection was only 33%, suggesting that TC clearly impacted the ability to 
detect this genomic alteration. The analysis of AR copy numbers provided an 
estimate of data reproducibility of cfDNA profiles across different whole-genome 
platforms.  
 
CTC DNA vs. cfDNA:  whole-genome copy number alteration analysis by aCGH 
After establishing the impact of TC on the detection of common genomic alteration in 
cfDNA using both low pass WGS and aCGH, we next compared CNAs in patients’ 
paired CTC DNA and cfDNA by identical aCGH methods across both the radium-223 
and PROPHECY prospective studies. For this analysis, we included 69 CTC DNA 
from 35 men (25 pre-treatment baseline samples and 40 longitudinal samples) and 
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72 paired cfDNA from 34 men (33 pre-treatment baseline and 39 longitudinal) with 
paired germline reference DNA (Figure 1A and B). In this comprehensive analysis, 
we focused on sixty common and recurrently altered genes that have been 
previously implicated with mCRPC for CNAs analysis in both CTCs and cfDNA [38]. 
We identified heterogeneity in the detection of multiple altered genomic regions in 
CTCs- and paired cfDNA samples, including common genomic gains in FOXA1 
(59% vs. 75%), KDM6A (52% vs. 18%), AR (46% vs. 63%), and MYC (17% vs. 21%) 
(Figure 2A). Similarly, common genomic losses included ZFHX3 (59% vs. 40%), 
FGFR2 (43% vs. 33%), PHLPP1 (36% vs. 29%), BRCA1 (26% vs. 28%), and PTEN 
(14% vs. 13%) (Figure 2B).  For example, at a focal or gene level, a representative 
gene view image of concordance in CTCs vs. cfDNA harboring AR copy gain and 
ZFHX3 copy loss with probes distributions are shown in Figure 2C and D, 
respectively. 
 
Further, we compared the prevalence of these CNAs from our cohort with publicly- 
available datasets in cBioportal [35]. The prevalence of these genomic alterations in 
both CTCs and cfDNA was similar to those reported in multiple primary and 
metastatic prostate cancer datasets, with copy gain or loss in the same direction as 
those identified in CTCs and cfDNA. For example, 52% (78/150) of SU2C/PCF 
mCRPC samples had AR gain, which is consistent with our AR copy gain detection 
in CTCs DNA and cfDNA (46% vs. 63%) (Figure 2E). In addition to AR, the 
prevalence of gain or loss of multiple additional genomic regions was confirmed in 
publicly-available prostate cancer data sets, including amplification of FOXA1, 
CYP11B1, and MYCN (Figure 2E), and deletions in ZFHX3, NCOR1, FGFR2, and 
NKX3-1 (Figure 2F). Thus, our findings suggest that aCGH consistently detects 
concordant CNAs in CTCs and cfDNA from men with mCRPC, similar to that 
reported from metastatic biopsies. 
 
To examine whether there are discordant genomic alterations between time- and 
patient-paired CTC DNA and cfDNA, we first analyzed the prevalence of genomic 
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alterations between 32-paired CTCs and cfDNA from 16 mCRPC men from the 
radium-223 treated cohort of men with mCRPC, including 14 baseline and 18 
longitudinal samples. We observed a high concordance in copy number gain of 
FOXA1 (86%) and AR (87%) between matched CTC and cfDNA sources, moderate 
concordance for copy gain of MYC (50%), NCOR2 (50%), AURKA (50%) and loss of 
ZFHX3 (47%) and PHLPP1 (45%), and low concordance between sources for gain 
of MYCN (11%), KDM6A (39%) and loss of BRCA1 (30%), RB1 (33%), and FGFR2 
(29%) in CTC and matched cfDNA (Figure S5A). For example, MYCN gain was 
detected in 28% of CTC DNA samples but was detected in only 9% of cfDNA 
samples. These data suggest significant variability in the detection of genomic 
alterations using these two different sources of tumor DNA.   
 
We next examined the degree of CNA discordance within each treatment cohort, 
where tumor heterogeneity was observed in both CTC and paired cfDNA. A number 
of discordances were observed between 32 paired CTCs and cfDNA (14 baseline 
and 18 progression) from the 16 men with mCRPC treated with radium-223, such as 
gain of CYP11B1 detection rate (59% vs. 3% in CTCs vs. cfDNA, respectively), and 
MYCN (28% vs. 9%), and copy loss in GRHL2 (75% vs. 19%), RUNX2 (63% vs. 
13%), PXN (38% vs. 0%), and NKX3-1(19% vs. 6%) (Figure 3A). These 
discordances were observed despite clear probe coverage of the genomic regions of 
interest in paired CTCs and cfDNA, as illustrated in Figure S6A and B. In addition, 
these discordant gain or loss of genomic regions were also observed in publicly 
available prostate cancer tissues data sets, as shown in Figure S7.  
 
To externally validate these CTC-discordant genomic alterations, we analyzed CTC 
vs. cfDNA concordance in the multicenter prospective PROPHECY study of men 
with mCRPC treated with abiraterone or enzalutamide, including 32 paired cases 
with matched CTCs and cfDNA samples from 16 mCRPC men (15 baseline and 17 
progression) treated with abiraterone or enzalutamide. Similar to our radium-223 
treated cohort, we detected concordant gains in FOXA1 (100%), AR (40%), MYC 
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(40%), and loss of ZFHX3 (58%), PHLPP1 (50%), BRCA1 (50%), RB1 (40%), and 
FGFR2 (50%) between paired CTC and cfDNA sources (Figure S5B).  
 
In the PROPHECY cohort, we likewise observed discordant gains in MYCN 
(detection frequency of 31% vs. 0%) and CYP11B1 (34% vs. 9%), and discordant 
loss in RUNX2 (47% vs. 3%) and PXN (28% vs. 3%) (Figure 3B), respectively. We 
next asked whether this CTC-discordance could be due to lowTC or due to high CTC 
counts in the paired samples. Surprisingly, however, we found similar rates of high 
CTC vs. cfDNA discordance even in those cfDNA cases with highTC or low CTCs 
(Figure 3C and D). Moreover, the prevalence of genomic alterations of these 
concordance/discordances were significantly higher in >=5 CTCs in comparison to 0, 
and 1-4 CTCs by CellSearch criteria (N=45 baseline, PROPHECY study) (Figure 
3E). In addition, we compared the overall genomic alterations, and genome 
discordance in CNAs at the whole-genome level in 21 paired CTCs and cfDNA 
based on their tumor content grouped into lowTC (n=12) and highTC (n=9). We 
observed a trend of increased in overall CNAs (Figure S8A), and genomic 
discordance of genomic regions with CTC DNA copy gain in highTC than lowTC 
samples, but no significant differences were observed in genomic regions with 
cfDNA copy gain or loss (Figure 3F-H, and Figure S8B and C). Further, to visualize 
inter- and intra-tumor heterogeneity among these CNAs in detail, the number of 
CTCs, and paired CTCs vs. cfDNA CNAs status of 60 genes from radium (top) and 
PROPHECY (bottom) studies are summarized in Figure S9A and B. Analysis of 
genomic copy gain agreement by Cohen’s Kappa in 64 paired CTCs and cfDNA 
CNAs was consistent with most of our previous concordance and discordance 
findings. However, we found low Cohen’s Kappa for AR gain, reflecting more 
abundance of AR gain detection in cfDNA over CTC DNA. Analysis of genomic copy 
loss agreement by Cohen’s Kappa, however, was variably consistent with our 
previous findings. The top agreement and disagreement between CTCs and cfDNA 
CNAs with Kappa scores are summarized in Table S3. Together, these data suggest 
that CTCs in some men with mCRPC have consistently different copy number 
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profiles as compared with paired cfDNA profiles, as exemplified by selected gene 
regions, which may be reflective of either biologic heterogeneity of the source of 
DNA or differences in detection for each assay related to CTC number or cfDNA 
concentration.   
 
Genomic and phenotypic evolution: heterogeneity and NEPC transformation 
To describe in detail the potential clinical significance of discordant CTC and cfDNA 
profiles, we collected paired CTCs and cfDNA with high tumor content from a 
PROPHECY cohort patient (# 809-33) at baseline and disease progression during 
treatment with abiraterone and enzalutamide. The patient had been determined to be 
negative for AR-V7 by the Epic AR-V7 assay [17] and had a CTC aCGH profile 
consistent with gains in AR, MYCN, FOXA1, and loss of BRCA1. His CTC phenotype 
suggested high tumor heterogeneity with an elevated Epic Shannon Index of 1.7 
[39]. Following continued disease progression on enzalutamide and docetaxel 
chemotherapy, the patient’s CTCs increased from 194 to 1,359, and his cfDNA 
concentration increased from 129 to 428 ng/2ml. These increases in cfDNA were 
accompanied by a rapid PSA rise and the development of soft tissue and liver 
metastases. A metastatic biopsy of a lymph node confirmed histologic transformation 
to small cell carcinoma (Figure 4).  His repeat CTC genomic analyses remained 
negative for AR-V7, but demonstrated an aCGH profile consistent with AR genomic 
loss, the persistence of MYCN gain and a small cell CTC and tissue phenotype 
suggestive of a neuroendocrine-like transformation [40] (Figure 4A). Interestingly, 
MYCN copy gain was found in longitudinal CTC samples but not in cfDNA despite 
the highTC in his cfDNA collected from the same time point. In addition, several new 
genomic alterations became dominant in this patient’s post-enzalutamide 
progression CTCs samples that were not detected in matched cfDNA samples 
(Figure 4B-D). The patient’s tumor cells also exhibited high nuclear to cytoplasmic 
ratio, inconspicuous nucleoli, foci of necrosis and abundant apoptotic debris, and 
PSA loss of expression, all of which are features characteristic for small cell 
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carcinoma. Immunohistochemical staining of pan-cytokeratin and synaptophysin 
confirmed the neuroendocrine differentiation of an epithelial lineage in this tumor 
while highlighting the minimal cytoplasm present in these tumor cells (Figure 4E-H).  
 
To assess the relevance of these findings in a broader context, we established that 
MYCN gain is one of the top discordant CNAs in PROPHECY 
abiraterone/enzalutamide treated mCRPC men (31% CTC vs. 0% cfDNA) (Figure 
4Ia). In support of the PROPHECY findings, MYCN gain was also observed to be 
discordant in 32 matched CTCs and cfDNA from 16 mCRPC men treated with 
radium-223 (28% MYCN gain detection in CTC vs. 9% in matched cfDNA) (Figure 
4Ib). In addition, MYCN gain was observed in multiple publicly-available prostate 
cancer datasets, including both primary and metastatic tumors (TCGA, SU2C, and 
NEPC) in cBioportal [35] (Figure 4Ic). Taken together, these data suggest that CTCs 
may discern clonal selection of AR-independent and treatment-emergent genomic 
events that may be contributing to enzalutamide resistance and may not be identified 
in cfDNA. 
 
Genomic discordance of osteomimicry genes in mCRPC 
Among those genes with discordant gains or losses in our mCRPC cohort (Figure 
3A and B) were genes related to osteoblast biology, suggesting a role for potential 
osteomimicry in metastatic dissemination in men with mCRPC [37, 41]. We identified 
discordant gains and losses in seven key osteoblastic regulating genes: ALPL 
(alkaline phosphatase), RUNX2 (runt-related transcription factor 2), BGLAP (bone 
gamma carboxyglutamate protein, osteocalcin), SPP1 (secreted phosphoprotein 1, 
osteopontin), CDH11 (osteoblast cadherin), TNFSF11 (tumor necrosis factor ligand 
superfamily 11 or RANKL) and SPARC (secreted protein acidic and cysteine-rich, 
osteonectin). When examined by aCGH in 32 paired CTCs and cfDNA DNA from 16 
mCRPC men, we found genomic gains in CTCs for ALPL (12%), CDH11 (19%), 
SPP1 (22%), and TNFSF11 (13%), whereas copy loss of RUNX2 was notable in 
63% of CTCs. Of these, 69% of RUNX2 copy loss cases also harbored highTC in 
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their matched cfDNA samples. Remarkably, however, we did not identify common 
gains or losses of these osteoblastic gene regulators in cfDNA samples by aCGH 
from the same patients at the same time points (Figure S10A). It is important to note 
that gains and losses at other loci were highly concordant in these same-paired 
samples using the same aCGH methodology, suggesting that differences in 
osteoblastic gene alterations found in CTCs and absent cfDNA were not due to 
differences in CTC number, cfDNA concentration, or assay sensitivity.  For example, 
we found common genomic gains in AR and FOXA1, and losses in PHLPP1 and 
BRCA1 in both CTCs and matched cfDNA from the same patients at the same time 
points, and while slight differences were noted in the frequency of these gains in the 
cfDNA, there was overall consistency between CTCs and cfDNA of these genes.  
 
We also observed discordant genomic findings of osteoblastic regulators in CTCs in 
our PROPHECY cohort of 32 CTCs and matched cfDNA from 16 patients. For 
example, we identified copy gains for these seven osteoblast genes in patients, 
including ALPL (19%), CDH11 (16%), SPP1 (9%), and TNFSF11 (6%) and SPARC 
(9%), whereas, copy loss of RUNX2 was notable in 47% of CTCs [19]. However, in 
matched cfDNA samples from the same patients, copy gain/loss of these key genes 
were not observed despite the collection of samples at the same time points and 
using the same aCGH method of detection, and despite highTC of many cfDNA 
samples (Figure S10B). In detail, the CNAs in osteomimicry genes in paired CTCs 
and cfDNA from radium (top) and PROPHECY (bottom) studies are summarized in 
File S2. These data, together with discordances of MYCN gain in CTCs, suggest 
that CTCs may harbor genomic alterations important to the metastatic biology of 
CRPC that is missed by examining only the cfDNA fraction. 
 
We next sought to validate the presence of key genomic alterations identified in our 
CTCs, particularly those discordant genes not found in cfDNA, in public datasets of 
men with mCRPC.  To explain if genomic alteration confers mRNA expression in 
mCRPC, we analyzed two independent prostate cancer datasets containing 286 
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metastatic tissue samples [38, 42], where both CNV and mRNA-expression profiling 
were performed simultaneously and analyzed in cBioportal [35]. We identified 
several CTC-discordant genes, such as KDM6A, UGT2B17, NRAS, and NCOR1, in 
which genomic loss correlated with lower mRNA expression and genomic gain 
correlated with higher mRNA expression in mCRPC tumor tissues (Figure S11). 
However, for several CTC discordant genes, we failed to identify a relationship 
between these CNAs and altered mRNA expression and CNAs. These data support 
our findings that several CTC-specific genomic alterations may be a common driving 
mechanism in mCRPC, but caution that some genomic alterations may not be 
associated with mRNA dysregulation or have functional significance, and thus 
require mechanistic and functional validation. 
 
Genomic loss of PTEN is prognostic for poorer survival in AR-V7 negative 
patients   
Finally, we sought to examine the clinical implications of CTC-specific genomic 
alterations in our PROPHECY study cohort. We focused our analyses on those men 
with mCRPC who tested negative for AR-V7 nuclear protein using the Epic AR-V7 
test [30, 33], given that these men have significantly heterogeneous clinical 
outcomes when treated with abiraterone or enzalutamide.  First, as a positive control 
biomarker, we examined the prognostic relevance of AR-V7 mRNA detection by the 
Johns Hopkins Adnatest method (JHU AR-V7) in CTCs of 40 baseline mCRPC men 
in the PROPHECY study who tested negative for AR-V7 by the Epic nuclear assay 
(Epic AR-V7) [16, 17]. A total of 18% (7/40) baseline CTCs samples were AR-V7 
mRNA positive (median CTC 45, range 3-194) by the JHU AR-V7 assay, but 
negative by Epic AR-V7 nuclear protein detection assay. The median radiographic 
PFS with abiraterone or enzalutamide treatment was significantly lower at 2.7 
months for AR-V7 positive disease as compared with 8.4 months for AR-V7-negative 
disease (HR 3.2, 95% CI, 1.4 – 7.4) (Figure 5A). These data support the relevance 
of JHU CTC AR-V7 positivity, even in Epic AR-V7 negative men. 
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Next, we examined common concordant CNAs in CTCs for their prognostic 
relevance in 40 Epic AR-V7 negative men with mCRPC treated with 
abiraterone/enzalutamide.  A total of 45% (18/40) cases harbored AR copy gain by 
aCGH. These patients with AR copy gain had a trend toward lower median PFS (4.7 
months) vs. copy neutral/loss (8.4 months, HR 1.6, 95% CI, 0.8 - 3.2) (Figure 5B), 
though these differences were not statistically significant. In addition, the median 
PFS of men with CTC PTEN loss was significantly lower at 3.4 months in 
comparison to 8.4 months for men without PTEN loss (HR 0.4, 95% CI, 0.2 – 0.8) 
(Figure 5C). Given the small sample size, we are unable to perform multivariable-
adjusted analyses including CTC enumeration or other clinical prognostic factors, 
and these results are hypothesis-generating only. 
 
We next explored the prognostic potential of common CTC-cfDNA discordant genes 
and their association with PFS in these 40 Epic AR-V7-negative men with mCRPC 
treated with abiraterone or enzalutamide. Patients with CTCs who had discordant 
copy gains in MYCN, BRCA2 or KDM5D, or had discordant copy loss of RUNX2 had 
shorter progression-free survival (PFS) times compared with patients whose CTCs 
were copy neutral for these genes. For example, median radiographic PFS was 3.5 
months for MYCN copy gain in CTCs compared with 8.4 months for copy neutral 
(HR= 1.9, 95% CI, 0.9 – 3.9) (Figure 5D). Similarly, for BRCA2, PFS was 
significantly shorter at 2.8 months for copy gain and 8.4 months for copy neutral 
(HR= 4.3, 95% CI, 1.9 – 9.8) (Figure 5E), whereas PFS for RUNX2 copy loss was 
3.8 months compared with 7.4 months for copy neutral (HR= 0.8, 95% CI, 0.4 – 1.6) 
(Figure 5F). The median PFS for additional concordant and discordant copy gains or 
losses are summarized in Figure S12A-F. Moreover, some gains/losses were not 
associated with outcomes, suggesting that just detection of an alteration as a 
surrogate of high CTC number is insufficient for prognostication, and those specific 
genomic alterations are likely critical. While we consider these results exploratory 
and hypothesis-generating, our analyses suggest the following: 1) both concordant 
This article is protected by copyright. All rights reserved.
and discordant CNAs in CTCs versus cfDNA may be clinically relevant and 
prognostic for outcomes with AR inhibitor therapy; 2) CTC genomic alterations 
provide a unique source of DNA (and RNA) as compared to cfDNA, and 3) these 












In this study of prospectively-collected blood samples from two independent cohorts 
of men with mCRPC, we identified critical discordances in a series of genes related 
to prostate cancer pathobiology in CTC DNA compared to patient- and time-paired 
cfDNA samples. Our study confirms that the detection of whole-genome alterations 
is feasible in the majority of patients, and we identified common concordantly-altered 
genes in CTCs and cfDNA, such as AR, FOXA1, and PTEN.  We identified strong 
concordance of AR genomic alterations between paired cfDNA samples using both 
aCGH and lpWGS in cases with high and low tumor content.  Interestingly, we found 
consistent discordances in CTC samples, which were identified in independent 
cohorts, even in the presence of high cfDNA tumor content, suggesting that the 
genomic copy discrepancies identified between CTC DNA and cfDNA sources are 
platform-independent and may suggest different biological processes. While 
detection of genomic alterations is challenging in the absence of CTCs or lowTC 
plasma samples, these data support divergent biology in CTCs that may have 
clinical implications for therapy and biomarker development. 
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We observed significant between-patient and longitudinal genomic heterogeneity of 
CTCs and cfDNA in mCRPC patients, suggesting the presence of patient-specific 
diversity as well as clonal evolution over time. The detection of CTC-specific 
genomic alterations was linked to 1) neuroendocrine and lineage plasticity 
regulators, such as MYCN gain, 2) osteomimicry regulators, such as RUNX2 loss, 
and 3) epigenetic regulators, such as KDM6A and KDM5D. These CTC-specific 
alterations were associated with shorter progression-free survival times with 
abiraterone or enzalutamide in AR-V7 negative men with mCRPC, suggesting that 
CTCs may harbor clinically-relevant genomic information that could be missed by 
focusing solely on cfDNA analysis.  Critically, these poor outcomes were present in 
AR-V7 negative men, an important group of patients with a wide range of clinical 
outcomes with AR inhibitor therapy. We identified variable concordance in CTC DNA 
vs. cfDNA CNAs depending on the specific gene, type of alteration, and CTC 
enumeration, possibly reflecting biologic variability and single-cell tumor 
heterogeneity.   
 
We also established that aCGH and lpWGS were highly concordant in detecting AR 
(89%) gain in the same cfDNA samples. We also showed in mCRPC that CTCs and 
cfDNA are largely concordant in key genes, likely reflecting the clonal origin of CTCs 
[43]. For example, AR and FOXA1 gains were commonly observed in both CTC and 
cfDNA compartments and mirrors that of public mCRPC datasets.  In a prospective 
study, Wyatt et al. (2017) compared genomic alterations in paired metastatic 
prostate cancer tissues and cfDNA using whole-exome sequencing and identified 
64.7% concordance in AR amplification detection [12]. Similarly, we also confirmed 
AR copy gain concordance between paired CTC DNA and cfDNA samples collected 
from the same patients and at the same time point from two-combined concordance 
across both datasets, and in highTC samples. The amplification of AR in baseline 
CTC DNA was also associated with shorter survival times. Hence, this aCGH assay 
is appropriate to reproducibly identify alterations of selected driver genes, such as 
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AR, which supports the development of liquid biopsy platforms using CTC or cfDNA-
based biomarkers to understanding potential resistance mechanisms in cancers at 
the molecular level [38, 44].  
 
Interestingly, we also observed a number of discordant genomic alterations that may 
be critical to tumor progression, drug resistance, and lethal disease heterogeneity 
[43]. For example, previous studies have shown that MYCN is amplified and capable 
of inducing a neuroendocrine-like prostate cancer phenotype, where it is thought to 
be involved in developing resistance to androgen deprivation therapy [45, 46]. In our 
PROPHECY study, MYCN copy gain was observed in 31% of CTCs from mCRPC, 
whereas, none of the paired cfDNA cases harbored copy gain. The presence of 
MYCN in CTCs was also associated with shorter PFS with abiraterone or 
enzalutamide treatment, which suggests that CTC DNA and not cfDNA, may be 
more useful biospecimen source of certain prognostic or predictive biomarkers, and 
supports the enrichment of NEPC-like CTCs and non-AR dependent mCRPC during 
hormonal therapy [47].  The lack of MYCN gain in cfDNA may relate to the fact that 
CTCs remain viable in the circulation and are not shedding sufficient DNA to be 
detected in the cfDNA assays.  More sensitive cfDNA assays may reduce this 
discordance with CTC DNA detection; however, our study illustrates the need for 
close attention to both assay sensitivity and biologic heterogeneity.  
 
Our observation of discordance in genes detected in CTC CNAs that regulate 
osteoblast biology suggests the importance of these genes to bone metastasis.  One 
hundred percent of the men in our two cohorts had bone metastases, and we 
identified genomic alterations in seven osteomimicry markers in mCRPC CTC and 
paired cfDNA from two independent clinical trials (NCT02204943 and 
NCT02269982) [19, 37].  These alterations in osteoblastic gene regulators, including 
ALPL, RUNX2, SPP1, CDH11, and TNFSF11, were present in CTCs and not in 
paired cfDNA. Moreover, the genomic alterations in these genes were confirmed in 
both datasets in the same direction of genomic alteration (gain or loss) for each 
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gene, suggesting that these genomic alterations may be important for metastasis to 
the bone. Furthermore, Cohen’s kappa analysis of CTCs and cfDNA showed that AR 
has a discordance in the opposite direction, with greater detection in cfDNA than 
CTC DNA.  This may be due to an increase in AR-expressing cells dying during 
hormonal therapy (abiraterone/enzalutamide).  While the other CTC discordant 
genes may be the resistant, living clones that survive differentially and do not 
contribute as much to the cfDNA pool  [32, 37], the AR-dependent genes may be 
more concordant (truncal) or discordant favoring cfDNA.  Functional validation and 
mechanistic studies are needed to validate further and determine the clinical 
relevance of these CTC discordant genes to bone metastasis formation.    
 
Our findings are limited by the small and exploratory nature of the present dataset 
and are considered hypothesis-generating. There are several key limitations of the 
present analysis. First, our sample size is small, and we lack sufficient power to 
conduct multivariable prognostic analyses of individual CTC-specific genomic 
alterations, adjusting for CTC enumeration and clinical prognostic factors, similar to 
what we have reported for AR-V7 [19].  Future studies will need to evaluate the 
independent prognostic utility of these CTC discordant alterations and characterize 
their functional relevance. Second, our CNA studies suggest that low tumor content 
will reduce the ability to detect such genomic alterations, either through low CTC 
enumeration or through low cfDNA tumor content, similar to findings by others [6, 8].  
However, our findings of CTC discordant alterations persisted even in samples with 
high tumor content, suggesting potentially real biologic divergence. Finally, DNA 
copy number alterations may not be associated with differences in mRNA or protein 
expression could be due to epigenetic repression, segment amplification, or partial 
gene amplification of chromatin regions that may influence mRNA expression, and 
single-copy differences may have little functional consequences vs. high-level gains 
or biallelic losses. To address this limitation, we examined CNA and mRNA 
expression in paired samples in public datasets and confirmed significant positive 
correlations between CNAs and mRNA for many key concordant and discordant 
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genes observed in CTC DNA, such as gains in AR, MYC, FOXA1, KAT6B, and 
KDM6A, and losses in PTEN, RB1, and ZFHX3. Other discordant genes, such as 
MYCN, are already established to be critically relevant to small cell prostate cancer 
divergence [46].  Further mechanistic studies of CTC divergent genes are needed to 
evaluate their impact on treatment resistance and metastasis biology.  
 
Our data establish that CTCs and cfDNA are valuable sources of genetic information 
that provide important, but potentially distinct and complementary information 
regarding tumor progression, treatment response/resistance, and metastasis biology. 
Additional larger studies of paired samples prospectively collected in clinically 
annotated datasets of patients with cancer in different disease states and during 
different treatments are needed to define whether CTCs, cfDNA, or a combined 
approach has greater clinical utility [48, 49]. Our collective data suggest that CTCs 
harbor critical genomic information that may be missed by cfDNA analysis alone.  
Yet, reliance on CTC genomic data alone has limitations because many patients with 
metastatic prostate cancer lack detectable CTCs, particularly in earlier disease 
settings, limiting the clinical utility of this approach [50, 51]. Therefore, analysis of 
both CTCs and cfDNA, as well as CTC or cell-free RNA and/or protein, could 
represent a valuable integrated approach. Our data support the need for the 
continued development of sensitive CTC DNA or RNA and cfDNA detection methods 
to identify clonal heterogeneity and the emergence of rare cells during the selection 
pressure of systemic therapies. 
 
In summary, we find that while CTC DNA and cfDNA CNAs are largely concordant, a 
range of discordant findings in CTCs suggests that CTCs may report on divergent 
tumor evolution and heterogeneity that may be missed by cfDNA analysis. Genomic 
alterations in AR signaling, critical lineage oncogenes or tumor suppressors, 
epigenetic regulators, and osteomimicry pathways support a variety of progression 
and metastatic pathways important to CRPC lineage plasticity and bone metastasis 
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biology. Efforts to functionally characterize these CTC-divergent genomic alterations 
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